Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Northwest Biotherapeutics: Still Another Rebuttal to a Feuerstein Attack Is Called For

Introduction

Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the…
Read more…

Refuting Feuerstein’s Latest Negative Blog on Northwest Biotherapeutics (NWBO, Buy, $7.56)

Before I Get Into This Article, a Word to My Subscribers

I want to apologize to my subscribers for a software…
Read more…

Northwest Biotherapeutics (NWBO, Buy, $7.59) What the 2014 10-K Had to Say about the Approval of DCVax-L under the German Early Access Program

Purpose of This Blog

The approval of DCVax-L under the hospital exemption early access program was a stunning positive in my…
Read more…

Highlighting A New Report on Dendritic Cell Cancer Vaccines

Northwest Biotherapeutics’ (NWBO) DCVax-L and ImmunoCellular Therapeutics’ ICT-107 are dendritic cell cancer vaccines that are in phase II trials for…
Read more…